Do analysts rate TRVN or CARM?

Carisma Therapeutics has a consensus price target of $1.00, indicating a potential upside of 999,900.00%. Given Carisma Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Carisma Therapeutics is more favorable than Trevena. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Trevena 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Carisma Therapeutics 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 2.67

Is TRVN or CARM more profitable?

Trevena has a net margin of 0.00% compared to Carisma Therapeutics' net margin of -254.28%. Company Net Margins Return on Equity Return on Assets Trevena N/A N/A -119.55% Carisma Therapeutics -254.28% N/A -192.17%

Is CMRA or TRVN more profitable?

Company Net Margins Return on Equity Return on Assets Comera Life Sciences N/A N/A N/A Trevena N/A N/A -119.55%

Is TRVN or EFTR more profitable?

Company Net Margins Return on Equity Return on Assets Trevena N/A N/A -119.55% eFFECTOR Therapeutics N/A N/A N/A

Is EVLO or TRVN more profitable?

Company Net Margins Return on Equity Return on Assets Evelo Biosciences N/A N/A N/A Trevena N/A N/A -119.55%

Which has higher earnings and valuation, CALA or TRVN?

Calithera Biosciences has higher earnings, but lower revenue than Trevena. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Calithera Biosciences N/A N/A -$39.65M N/A N/A Trevena $443K 0.00 -$40.29M -$47.04 N/A

Is CALA or TRVN more profitable?

Company Net Margins Return on Equity Return on Assets Calithera Biosciences N/A N/A N/A Trevena N/A N/A -119.55%

Trevena (TRVN) Competitors

$0.0010 0.00 (0.00%)

As of 06/3/2026

Compare

TRVN vs. CARM, CMRA, EFTR, EVLO, and CALA

Should you buy Trevena stock or one of its competitors? MarketBeat compares Trevena with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Trevena include Carisma Therapeutics (CARM), Comera Life Sciences (CMRA), eFFECTOR Therapeutics (EFTR), Evelo Biosciences (EVLO), and Calithera Biosciences (CALA). These companies are all part of the "pharmaceutical products" industry.

How does Trevena compare to Carisma Therapeutics?

Trevena (NASDAQ:TRVN) and Carisma Therapeutics (NASDAQ:CARM) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, valuation, institutional ownership, media sentiment, risk, profitability, dividends and earnings.

Trevena has a net margin of 0.00% compared to Carisma Therapeutics' net margin of -254.28%.

Company	Net Margins	Return on Equity	Return on Assets
Trevena	N/A	N/A	-119.55%
Carisma Therapeutics	-254.28%	N/A	-192.17%

Trevena has a beta of 0.56, suggesting that its share price is 44% less volatile than the broader market. Comparatively, Carisma Therapeutics has a beta of 0.8, suggesting that its share price is 20% less volatile than the broader market.

Trevena has higher earnings, but lower revenue than Carisma Therapeutics. Trevena is trading at a lower price-to-earnings ratio than Carisma Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Trevena	$443K	0.00	-$40.29M	-$47.04	N/A
Carisma Therapeutics	$10.77M	0.00	-$60.48M	$0.73	0.00

Carisma Therapeutics has a consensus price target of $1.00, indicating a potential upside of 999,900.00%. Given Carisma Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Carisma Therapeutics is more favorable than Trevena.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Trevena	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Carisma Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.67

13.6% of Trevena shares are owned by institutional investors. Comparatively, 44.3% of Carisma Therapeutics shares are owned by institutional investors. 2.7% of Trevena shares are owned by insiders. Comparatively, 6.9% of Carisma Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

In the previous week, Trevena's average media sentiment score of 0.00 equaled Carisma Therapeutics'average media sentiment score.

Company	Overall Sentiment
Trevena	Neutral
Carisma Therapeutics	Neutral

Summary

Carisma Therapeutics beats Trevena on 10 of the 14 factors compared between the two stocks.

How does Trevena compare to Comera Life Sciences?

Comera Life Sciences (NASDAQ:CMRA) and Trevena (NASDAQ:TRVN) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their profitability, valuation, institutional ownership, dividends, risk, media sentiment, analyst recommendations and earnings.

In the previous week, Comera Life Sciences' average media sentiment score of 0.00 equaled Trevena'saverage media sentiment score.

Company	Overall Sentiment
Comera Life Sciences	Neutral
Trevena	Neutral

Company	Net Margins	Return on Equity	Return on Assets
Comera Life Sciences	N/A	N/A	N/A
Trevena	N/A	N/A	-119.55%

13.6% of Trevena shares are held by institutional investors. 8.9% of Comera Life Sciences shares are held by company insiders. Comparatively, 2.7% of Trevena shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Comera Life Sciences has higher revenue and earnings than Trevena. Trevena is trading at a lower price-to-earnings ratio than Comera Life Sciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Comera Life Sciences	$1.00M	0.00	-$18M	-$0.31	N/A
Trevena	$443K	0.00	-$40.29M	-$47.04	N/A

Comera Life Sciences has a beta of 1.06, meaning that its stock price is 6% more volatile than the broader market. Comparatively, Trevena has a beta of 0.56, meaning that its stock price is 44% less volatile than the broader market.

Summary

Comera Life Sciences beats Trevena on 6 of the 8 factors compared between the two stocks.

How does Trevena compare to eFFECTOR Therapeutics?

Trevena (NASDAQ:TRVN) and eFFECTOR Therapeutics (NASDAQ:EFTR) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, risk, dividends, analyst recommendations, institutional ownership, media sentiment, profitability and earnings.

Trevena has a beta of 0.56, meaning that its stock price is 44% less volatile than the broader market. Comparatively, eFFECTOR Therapeutics has a beta of 2.4, meaning that its stock price is 140% more volatile than the broader market.

13.6% of Trevena shares are held by institutional investors. Comparatively, 57.7% of eFFECTOR Therapeutics shares are held by institutional investors. 2.7% of Trevena shares are held by company insiders. Comparatively, 4.7% of eFFECTOR Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

eFFECTOR Therapeutics has lower revenue, but higher earnings than Trevena. Trevena is trading at a lower price-to-earnings ratio than eFFECTOR Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Trevena	$443K	0.00	-$40.29M	-$47.04	N/A
eFFECTOR Therapeutics	N/A	N/A	-$35.81M	-$13.08	N/A

In the previous week, Trevena's average media sentiment score of 0.00 equaled eFFECTOR Therapeutics'average media sentiment score.

Company	Overall Sentiment
Trevena	Neutral
eFFECTOR Therapeutics	Neutral

Company	Net Margins	Return on Equity	Return on Assets
Trevena	N/A	N/A	-119.55%
eFFECTOR Therapeutics	N/A	N/A	N/A

Summary

eFFECTOR Therapeutics beats Trevena on 7 of the 8 factors compared between the two stocks.

How does Trevena compare to Evelo Biosciences?

Evelo Biosciences (NASDAQ:EVLO) and Trevena (NASDAQ:TRVN) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, dividends, earnings, profitability, valuation, media sentiment, institutional ownership and analyst recommendations.

Company	Net Margins	Return on Equity	Return on Assets
Evelo Biosciences	N/A	N/A	N/A
Trevena	N/A	N/A	-119.55%

0.3% of Evelo Biosciences shares are held by institutional investors. Comparatively, 13.6% of Trevena shares are held by institutional investors. 1.0% of Evelo Biosciences shares are held by insiders. Comparatively, 2.7% of Trevena shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Evelo Biosciences has a beta of 2.03, indicating that its share price is 103% more volatile than the broader market. Comparatively, Trevena has a beta of 0.56, indicating that its share price is 44% less volatile than the broader market.

In the previous week, Evelo Biosciences had 1 more articles in the media than Trevena. MarketBeat recorded 1 mentions for Evelo Biosciences and 0 mentions for Trevena. Evelo Biosciences' average media sentiment score of 0.00 equaled Trevena'saverage media sentiment score.

Company	Overall Sentiment
Evelo Biosciences	Neutral
Trevena	Neutral

Trevena has higher revenue and earnings than Evelo Biosciences. Trevena is trading at a lower price-to-earnings ratio than Evelo Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Evelo Biosciences	N/A	N/A	-$114.53M	-$8.81	N/A
Trevena	$443K	0.00	-$40.29M	-$47.04	N/A

Summary

Evelo Biosciences beats Trevena on 5 of the 9 factors compared between the two stocks.

How does Trevena compare to Calithera Biosciences?

Calithera Biosciences (NASDAQ:CALA) and Trevena (NASDAQ:TRVN) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their risk, profitability, earnings, dividends, institutional ownership, media sentiment, analyst recommendations and valuation.

Calithera Biosciences has a beta of -1.32, meaning that its share price is 232% less volatile than the broader market. Comparatively, Trevena has a beta of 0.56, meaning that its share price is 44% less volatile than the broader market.

Company	Net Margins	Return on Equity	Return on Assets
Calithera Biosciences	N/A	N/A	N/A
Trevena	N/A	N/A	-119.55%

13.6% of Trevena shares are held by institutional investors. 6.6% of Calithera Biosciences shares are held by company insiders. Comparatively, 2.7% of Trevena shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

In the previous week, Calithera Biosciences had 1 more articles in the media than Trevena. MarketBeat recorded 1 mentions for Calithera Biosciences and 0 mentions for Trevena. Calithera Biosciences' average media sentiment score of 0.00 equaled Trevena'saverage media sentiment score.

Company	Overall Sentiment
Calithera Biosciences	Neutral
Trevena	Neutral

Calithera Biosciences has higher earnings, but lower revenue than Trevena.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Calithera Biosciences	N/A	N/A	-$39.65M	N/A	N/A
Trevena	$443K	0.00	-$40.29M	-$47.04	N/A

Summary

Calithera Biosciences and Trevena tied by winning 4 of the 8 factors compared between the two stocks.

Get Trevena News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TRVN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

TRVN vs. The Competition

Export

Metric	Trevena	Pharmaceutical Industry	Medical Sector	NASDAQ Exchange
Market Cap	$1K	$950.03M	$6.45B	$12.42B
Dividend Yield	N/A	4.84%	2.69%	5.22%
P/E Ratio	0.00	1.50	23.89	24.35
Price / Sales	0.00	121.50	524.38	119.30
Price / Cash	N/A	20.06	41.27	57.13
Price / Book	0.00	8.11	10.06	6.74
Net Income	-$40.29M	-$3.91M	$3.56B	$337.03M
7 Day Performance	N/A	-0.67%	-0.60%	0.24%
1 Month Performance	N/A	N/A	N/A	-1.60%
1 Year Performance	N/A	113.93%	29.29%	34.04%

Trevena Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
TRVN Trevena	N/A	$0.00 flat	N/A	-99.9%	$1K	$443K	N/A	40
CARM Carisma Therapeutics	2.2462 of 5 stars	$0.00 flat	$1.00 +999,900.0%	-99.9%	$4K	$10.77M	0.00	20
CMRA Comera Life Sciences	N/A	N/A	N/A	N/A	$3K	$1.00M	N/A	2
EFTR eFFECTOR Therapeutics	N/A	$0.00 +20.0%	N/A	N/A	$3K	N/A	N/A	10	Gap Down
EVLO Evelo Biosciences	N/A	N/A	N/A	N/A	$2K	N/A	N/A	120

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:TRVN) was last updated on 6/4/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trevena (TRVN) Competitors

TRVN vs. CARM, CMRA, EFTR, EVLO, and CALA

How does Trevena compare to Carisma Therapeutics?

Summary

How does Trevena compare to Comera Life Sciences?

Summary

How does Trevena compare to eFFECTOR Therapeutics?

Summary

How does Trevena compare to Evelo Biosciences?

Summary

How does Trevena compare to Calithera Biosciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TRVN vs. The Competition

Trevena Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Trevena (TRVN) Competitors

TRVN vs. CARM, CMRA, EFTR, EVLO, and CALA

How does Trevena compare to Carisma Therapeutics?

Is TRVN or CARM more profitable?

Which has more volatility and risk, TRVN or CARM?

Which has higher valuation and earnings, TRVN or CARM?

Do analysts rate TRVN or CARM?

Do insiders & institutionals have more ownership in TRVN or CARM?

Does the media prefer TRVN or CARM?

Summary

How does Trevena compare to Comera Life Sciences?

Does the media favor CMRA or TRVN?

Is CMRA or TRVN more profitable?

Do institutionals & insiders hold more shares of CMRA or TRVN?

Which has stronger earnings and valuation, CMRA or TRVN?

Which has more risk and volatility, CMRA or TRVN?

Summary

How does Trevena compare to eFFECTOR Therapeutics?

Which has more risk and volatility, TRVN or EFTR?

Do insiders & institutionals believe in TRVN or EFTR?

Which has preferable valuation & earnings, TRVN or EFTR?

Does the media refer more to TRVN or EFTR?

Is TRVN or EFTR more profitable?

Summary

How does Trevena compare to Evelo Biosciences?

Is EVLO or TRVN more profitable?

Do insiders & institutionals believe in EVLO or TRVN?

Which has more volatility & risk, EVLO or TRVN?

Does the media favor EVLO or TRVN?

Which has higher earnings and valuation, EVLO or TRVN?

Summary

How does Trevena compare to Calithera Biosciences?

Which has more risk and volatility, CALA or TRVN?

Is CALA or TRVN more profitable?

Do insiders and institutionals have more ownership in CALA or TRVN?

Does the media favor CALA or TRVN?

Which has higher earnings and valuation, CALA or TRVN?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TRVN vs. The Competition

Trevena Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools